Skip to content Skip to footer
Subscribe Now
EVENTS

Digi-Tech Pharma & AI 2027 | May 11-12 | London, UK

The pharmaceutical and healthcare industries are entering a new era of technology-led transformation, with artificial intelligence, machine learning, data science, informatics, and advanced data management reshaping how medicines are discovered, developed, and delivered. Against this backdrop, Digi-Tech Pharma & AI 2027 will bring together senior professionals, technology leaders, decision-makers, and innovators from the pharmaceutical, biotechnology,…
August 19, 2026

Read more

EXCLUSIVE

Oncolytics Biotech’s Next Chapter: Jared Kelly on Advancing Pelareorep Toward Approval  

Shots  Pelareorep is gaining regulatory momentum through multiple FDA interactions and Fast Track designations, providing greater clarity around potential registration pathways and shaping Oncolytics’ clinical development and partnership strategy.  REO-033 could mark a pivotal step toward registration as the randomized study in RAS-mutant MSS metastatic colorectal cancer builds on encouraging clinical data and has the potential to become…
August 17, 2026

Read more

MAGAZINE

PharmaShots Magazine-Aug-2026 Edition

Shots:  This edition explores Tailored Therapy, Smarter Decisions: AI in Personalized Medicine, highlighting how artificial intelligence, machine learning, multi-omics, real-world data, and predictive analytics are transforming personalized medicine into a more precise, data-driven, and patient-centric approach to care, enabling better patient stratification, treatment selection, and clinical decision-making. Through expert perspectives, feature stories, and industry insights,…
August 13, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in July 2026 

Shots:  The US FDA approved six notable therapies in July 2026 across nephrology, oncology, cardiometabolic disease, ophthalmology, and neuropsychiatry, highlighting continued progress in specialty and chronic disease treatment.   Key approvals included Trutakna (atacicept) for IgA nephropathy, Revtorpyk (gedatolisib) for HR+/HER2- breast cancer, Lipfendra (enlicitide) for hypercholesterolemia, Jideytro (zidesamtinib) for ROS1-positive NSCLC, Lytenava (bevacizumab-vikg) for wet AMD, and Simtriyo (centanafadine) for ADHD, expanding treatment options across diverse patient…
August 11, 2026

Read more

VIEWPOINTS

A Promise Made at Six: The Winding Road to Cancer Research

An Interview with Priyanka Joshi, Associate Scientist in Analytical Development Introduction Cancer remains one of the world's greatest healthcare challenges, driving scientists to develop more effective and precise treatment approaches. Among the most promising innovations are cell therapies, which harness the body's own immune system to fight cancer. Behind these advances are scientists working to…
August 5, 2026

Read more

CXO TALKS

CXO Talks Podcast | Building Smarter Biotech: Venkat Nelabhotla, CEO of Vyome Holdings, on Driving Innovation Across the US–India Corridor

Shots: In a thought-provoking conversation with PharmaShots CXO Talks, Venkat Nelabhotla, Co-Founder, President & CEO of Vyome Holdings, discussed how disciplined execution, strategic capital allocation, and focused innovation are shaping the company's approach to developing therapies for high unmet medical needs while strengthening the US–India biotech innovation corridor. Venkat highlighted Vyome's strategy of leveraging drug…
July 22, 2026

Read more

EXCLUSIVE

Gona Aziz at HLTH Europe 2026 on the Convergence of AI & 5T MRI: United Imaging’s Strategy for Advancing Precision Healthcare 

Shots  United Imaging is advancing the future of radiology through the convergence of ultra-high-field imaging and AI, with the uMR Jupiter 5T enabling unprecedented anatomical and functional visualization while next-generation AI transforms imaging data into actionable clinical insights that support earlier diagnosis, precision medicine, and personalized patient care.  At HLTH Europe 2026, the company highlighted how 5T whole-body MRI expands clinical…
July 20, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in June 2026 

Shots:  The US FDA approved three notable therapies in June 2026, spanning diagnostic imaging, infectious diseases, and ophthalmology, highlighting continued progress in precision diagnostics, antimicrobial innovation, and rare disease treatment.  Key approvals included Ambelvist (enhanced MRI detection of lesions), Utebzi (complicated urinary tract infections, including pyelonephritis), and Lumvoa (thyroid eye disease), expanding treatment and diagnostic options for patients with diverse clinical…
July 14, 2026

Read more

VIEWPOINTS

Michael Wysocki on Precision Molecular Imaging & PSMA PET Innovation: Blue Earth Diagnostics’ Vision for Personalized Prostate Cancer Care

Shots:  Blue Earth Diagnostics is advancing precision molecular imaging in prostate cancer through its F-18 PET imaging portfolio, with POSLUMA and Axumin designed to improve disease localization, support earlier clinical decision-making, and enhance physician confidence, particularly in patients experiencing biochemical recurrence.  At SNMMI 2026, the company presented new evidence highlighting POSLUMA's strong detection performance at low PSA levels, reduced urinary…
July 13, 2026

Read more

INSIGHTS+ TOP 20

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025) 

Shots:  PharmaShots' latest report chronicles the transformation of the global biopharma industry from 2006–2025, highlighting how innovation, strategic M&A, AI adoption, and evolving commercialization strategies have reshaped the competitive landscape while companies navigated patent cliffs, pricing pressures, and shifting market dynamics.   The report tracks the rise and fall of leading biopharma companies over two decades driven by…
July 10, 2026

Read more

Load more